CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response ...
Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors ...
By helping forge a connection between oral health and systemic conditions, brokers can strengthen client relations and differentiate their services in a competitive market.
Data to be presented will highlight the progress of SAB BIO’s lead program, SAB-142, a potentially best-in-class, disease-modifying, redosable immunotherapy in clinical development for delaying the ...
Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data In Oral Presentation At The 2025 ASH Annual Meeting. NANJING, China, Dec. 7, 2025 /PRNewswire/ -- From December 6 to 9, 2025, the 67th ...
MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmu ...
11h
RYIM 2025 Brings Together Young Scientific Minds In Mumbai To Drive Future Research Collaboration
Mentor talks by Prof. Vidita Vaidya (TIFR) and Dr. Mukund Goswami (CIFE) encouraged young researchers to pursue meaningful ...
State lawmakers heard the presentation on traffic stop demographics at a Joint Transportation Committee meeting Dec. 3.
A last-ditch appeal to the Michigan Supreme Court was filed Monday in the state Senate’s lawsuit against the House of ...
Survivors of the 1941 Japanese bombing of Pearl Harbor have long been the center of a remembrance ceremony held each year on ...
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team and Dr. Claire ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback